Advancing cell-based therapy in sepsis: An anesthesia outlook

Sepsis poses a health challenge globally owing to markedly high rates of morbidity and mortality. Despite employing bundle therapy over two decades, approaches including transient organ supportive therapy and clinical trials focusing on signaling pathways have failed in effectively reversing multipl...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 137; no. 13; pp. 1522 - 1534
Main Authors Ye, Hui, Zou, Xiaoyu, Fang, Xiangming
Format Journal Article
LanguageEnglish
Published China Lippincott Williams & Wilkins Ovid Technologies 05.07.2024
Lippincott Williams & Wilkins
Wolters Kluwer
Subjects
Adaptive immunity
Anesthesia
Clinical outcomes
Clinical trials
Cytokines
Genome editing
Hemodynamics
Homeostasis
Immune system
Immunotherapy
Infections
Inflammation
Medical personnel
Medical prognosis
Metabolism
Morbidity
Mortality
Pathogens
Pathophysiology
Review
Sepsis
Stem cells
Trauma
Online AccessGet full text

Cover

More Information
Summary:Sepsis poses a health challenge globally owing to markedly high rates of morbidity and mortality. Despite employing bundle therapy over two decades, approaches including transient organ supportive therapy and clinical trials focusing on signaling pathways have failed in effectively reversing multiple organ failure in patients with sepsis. Prompt and appropriate perioperative management for surgical patients with concurrent sepsis is urgent. Consequently, innovative therapies focused on remedying organ injuries are necessitated. Cell therapy has emerged as a promising therapeutic avenue for repairing local damage to vital organs and restoring homeostasis during perioperative treatment for sepsis. Given the pivotal role of immune cell responses in the pathogenesis of sepsis, stem cell-based interventions that primarily modulate immune responses by interacting with multiple immune cells have progressed into clinical trials. The strides made in single-cell sequencing and gene-editing technologies have advanced the understanding of disease-specific immune responses in sepsis. Chimeric antigen receptor (CAR)-immune cell therapy offers an intriguing option for the treatment of sepsis. This review provides a concise overview of immune cell therapy, its current status, and the strides made in the context of sepsis research, discussing potential strategies for the management of patients with sepsis during perioperative stages.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0366-6999
2542-5641
2542-5641
DOI:10.1097/CM9.0000000000003097